The aryl hydrocarbon receptor (AhR) participates in the differentiation of mouse regulatory T cells (T reg cells) and interleukin 17 (IL-17)-producing helper T cells (T H 17 cells), but its role in human T cell differentiation is unknown. We investigated the role of AhR in the differentiation of human induced T reg cells (iT reg cells). We found that AhR activation promoted the differentiation of CD4 + Foxp3 − T cells, which produce IL-10 and control responder T cells through granzyme B. However, activation of AhR in the presence of transforming growth factor-b1 induced Foxp3 + iT reg cells, which suppress responder T cells through the ectonucleoside triphosphate diphosphohydrolase CD39. The induction of functional Foxp3 + iT reg cells required coordinated action of the transcriptional regulators Smad1 and Aiolos. Thus, AhR is a potential target through which functional iT reg cells could be induced in human autoimmune disorders.
A r t i c l e s
In healthy people, the immune response is controlled by several subsets of regulatory T cells (T reg cells) that are generated in the thymus (natural T reg ) and also in the periphery in response to various tolerogenic stimuli (induced T reg cells (iT reg cells) 1 . One of these subsets is a population of CD4 + T cells characterized by expression of the transcription factor Foxp3 (A002750) 1 . In mice, Foxp3 is a specific marker for T reg cells, and forced expression of Foxp3 (refs. 2,3) or its induction with transforming growth factor-β1 (TGF-β1) 4 promotes the differentiation of functional Foxp3 + T reg cells. In humans, however, Foxp3 expression is not always linked to regulatory function: activated T cells transiently express Foxp3 (refs. 5,6) , and neither forced overexpression of Foxp3 (ref. An additional subset of CD4 + T reg cells are the Foxp3 − IL-10 + T cells, called type 1 regulatory T cells (Tr1 cells), initially generated after repeated cycles of in vitro stimulation in the presence of interleukin 10 (IL-10) 9 . Additional regimens, such as stimulation in the presence of IL-27, the addition of antibody to CD46 (anti-CD46), treatment with dexamethasone and vitamin D, or the administration of rapamycin and IL-10 can also promote the differentiation of Tr1 cells 10, 11 . Tr1 cells are important in immune homeostasis and the control of graftversus-host disease 10 , but the signaling pathways that control their differentiation, especially in humans, are largely unknown.
Mice that lack functional Foxp3 + T reg cells develop severe autoimmunity 2 , and T reg cell deficits have been described in several human autoimmune diseases 12 . Because T reg cells have positive effects in experimental models of autoimmunity, their induction is viewed as a promising approach for the treatment of human autoimmune disorders. Several methods have been reported to differentiate and expand human Foxp3 + iT reg cell populations in vitro, but their ability to produce substantial numbers of functional cells in a consistent manner is limited 13 . It is therefore important to characterize the pathways that control the generation of functional human Foxp3 + iT reg cells.
The ligand-activated transcription factor aryl hydrocarbon receptor (AhR (A000229)) controls the differentiation of mouse T reg cells and IL-17-producing helper T cells (T H 17 cells) in vitro and in vivo [14] [15] [16] [17] [18] [19] [20] . Activation of AhR by its high-affinity ligand TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) in vivo results in the induction of CD4 + CD25 + Foxp3 + T reg cells 14 . These cells are functional and suppress the development of experimental autoimmune encephalomyelitis 14 , experimental autoimmune uveoretinitis 18 and spontaneous autoimmune diabetes 21 . However, it is not known whether AhR signaling can be exploited to promote the differentiation of functional human iT reg cells.
To address that question, we investigated the effect of AhR ligands on the differentiation of human Tr1 and Foxp3 + iT reg cells. We found that AhR activation induced human Tr1-like cells that suppressed responder T cells by a granzyme B-dependent mechanism. In addition, AhR activation in the presence of TGF-β1 induced the differentiation A r t i c l e s of functional human Foxp3 + iT reg cells that suppressed responder T cells through the ectonucleoside triphosphate diphosphohydrolase CD39. The induction of functional Foxp3 + iT reg cells by the concurrent activation of TGF-β1 and AhR signaling was mediated, at least partially, by the transcription factors Smad1 and Aiolos. Thus, our data suggest that AhR might be an important target for the generation of various types of T reg cells in humans and that nontoxic AhR ligands could provide new drug candidates for the induction of T reg cells in vivo and for the management of autoimmune diseases.
RESULTS

AhR activation induces T cells that produce IL-10
AhR participates in the differentiation of mouse Foxp3 + T reg cells [14] [15] [16] [17] [18] . To investigate whether AhR contributes to the differentiation of human T reg cells, we isolated naive CD4 + T cells from peripheral blood mononuclear cells obtained from healthy donors and activated them with anti-CD3, anti-CD28 and IL-2 with or without the AhR ligand TCDD (Supplementary Fig. 1 ). Naive T cells differentiated in the presence of TCDD showed a much lower proliferative response after restimulation (Fig. 1a) . Moreover, T cell activation in the presence of TCDD upregulated expression of the AhR target gene CYP1A1 (which encodes a cytochrome p450 protein) 22 but did not modify the expression of AHR, as measured by quantitative real-time PCR (Fig. 1b) .
To characterize the phenotype of the human T cells treated with TCDD, we analyzed expression of the lineage-specific transcription factor genes FOXP3 (T reg cells), GATA3 (T helper type 2 (T H 2) cells), TBX21 (T H 1 cells) and RORC (T H 17 cells). Activation of naive T cells in the presence of TCDD led to significant upregulation of FOXP3 expression (Fig. 1c) . However, we did not detect upregulation of Foxp3 by flow cytometry (Supplementary Fig. 2 ). We detected no change in the expression of GATA3 or RORC, but there was significantly lower TBX21 expression after treatment with TCDD (Fig. 1c) . In addition, TCDD-treated T cells expressed significantly more IL10 concomitant with significantly lower expression of IFNA1 (encoding interferon-γ), IL2 and IL17A than that of untreated T cells (Fig. 1d) . We found no difference in the expression of TNF or TGFB1 (Fig. 1d) . We obtained similar results when we activated human naive CD4 + T cells in the presence of the AhR ligand FICZ (6-formylindolo [3,2-b] carbazole; data not shown).
AhR transactivates the IL10 promoter
The transcription factor c-Maf (A003947) controls the synthesis of IL-10 by mouse T cells [23] [24] [25] . To further characterize the IL-10-producing T cells induced by AhR activation, we studied the expression of MAF (which encodes c-Maf) by quantitative real-time PCR. We found that MAF was expressed by TCDD-treated and IL-27 induced Tr1 cells, but its expression was not significantly higher in those cells than in control cells (Supplementary Fig. 3 ).
To investigate whether the effect of TCDD on IL10 expression was mediated by AhR, we knocked down AhR expression with small interfering RNA (siRNA). After 6 d, siRNA decreased the expression of AHR mRNA by 75% (Supplementary Fig. 4a) . Correspondingly, the knockdown of AHR suppressed the induction of IL10 by TCDD (Supplementary Fig. 4a ). Thus, AhR controls IL10 expression by TCDD-treated T cells.
Given the importance of AhR for the expression of IL10 by TCDDtreated T cells, we hypothesized that AhR transactivates the human IL10 promoter. Moreover, given the expression of MAF by TCDDtreated cells (Supplementary Fig. 3 ) and its reported interaction with the mouse Il10 promoter 25 , we investigated the role of c-Maf in regulating human IL10 expression. We used bioinformatics analysis to identify a potential AhR-binding site (xenobiotic response element (XRE)) that partially overlaps with a c-Maf-recognition element (MARE) in the IL10 promoter (Supplementary Fig. 4b ).
To determine whether AhR can bind the XRE in the IL10 promoter, we used electrophoretic mobility-shift assay to study the interaction between an oligonucleotide containing the XRE and in vitro-translated AhR protein in complex with the AhR nuclear translocator. In vitro-translated AhR-AhR nuclear translocator complexes bound the XRE in the IL10 promoter, and this interaction was significantly lower after the addition of an excess of a competitor oligonucleotide containing an XRE found in CYP1A1 ( Supplementary  Fig. 4c ). To investigate whether AhR interacts with the XRE in the IL10 promoter in TCDD-treated cells, we used chromatin immunoprecipitation (ChIP) assays. AhR bound substantially to the IL10 promoter region that contained the XRE in TCDD-treated T cells but not in control T cells (Supplementary Fig. 4d) . We also detected a substantial interaction between c-Maf and the MARE in the IL10 promoter in TCDD-treated cells (Supplementary Fig. 4d ). Thus, AhR and c-Maf interact with the XRE and MARE, respectively, in the IL10 promoter in TCDD-treated cells.
To analyze the functional relevance of the binding of AhR and c-Maf to the IL10 promoter, we did reporter assays using a construct containing the firefly luciferase gene under the control of the human IL10 promoter 26 . AhR and c-Maf separately transactivated the IL10 promoter; this transactivation was greater after activation of transfected Jurkat cells with anti-CD3 and anti-CD28 (Supplementary Fig. 4e) . Notably, cotransfection with plasmids encoding both AHR and MAF resulted in an additive transactivation of IL10 ( Supplementary  Fig. 4e) . Similarly, forced overexpression of AHR in naive human CD4 + T cells followed by treatment with TCDD triggered IL10 expression, which was further upregulated by forced coexpression of MAF A r t i c l e s (Supplementary Fig. 4f ). In summary, these data suggest that AhR and c-Maf act together to control the transcription of IL10. It has been shown that c-Maf interacts physically with other transcription factors whose responsive elements are located close to MARE motifs in target genes 27 . Therefore, we investigated the interaction between AhR and c-Maf in coimmunoprecipitation experiments with constructs encoding AhR tagged with hemagglutinin and c-Maf tagged with the red fluorescent protein mCherry. We found that AhR and c-Maf precipitated together when we used anti-hemagglutinin or anti-mCherry but not when we used an isotype-matched control antibody (Supplementary Fig. 4g ). These data suggest that AhR interacts with c-Maf to control the transcriptional activity of the IL10 promoter.
AhR activation induces human Tr1-like cells
The production of IL-10 and the lower proliferative response of TCDD-treated T cells resembled the phenotype of Tr1 cells, which have in vitro suppressive activity 9 . We therefore analyzed the suppressive activity of TCDD-treated T cells in coculture assays. Human TCDD-treated T cells showed suppressive activity in vitro (Fig. 2a) . This suppressive activity was controlled by AhR, as it was abrogated when we knocked down AHR expression with a specific siRNA (Fig. 2b) . To further characterize the suppressive activity of the IL-10-producing T cells induced by AhR activation, we re-sorted TCDD-treated T cells, washed them extensively and cultured them together with responder T cells stained with annexin V and 7-aminoactinomycin D (7-AAD) after 3 d of coincubation. Coincubation of responder T cells with TCDD-treated T cells resulted in a greater frequency of annexin V-positive, 7-AAD − (early apoptotic) cells and annexin V-positive, 7-AAD + (late apoptotic and/or dead) cells (Fig. 2c,d ), which suggested that suppressive TCDD-treated T cells trigger apoptosis in responder T cells.
T reg cells use several mechanisms to control the activity of effector T cells 28 . Using a Transwell system, we found that the suppressive activity of TCDD-treated cells required cell contact (Fig. 3a) . Granzyme-triggered apoptosis can mediate the suppressive activity of Tr1 cells in a cell contact-dependent manner 29 , so we used quantitative real-time PCR to analyze the expression of GZMA (encoding granzyme A) and GZMB (encoding granzyme B) in TCDD-treated T cells. We found significantly higher GZMB expression in TCDDtreated T cells (Fig. 3b) but no significant change in the expression of GZMA (data not shown). We also found significantly higher granzyme A r t i c l e s B expression when we used flow cytometry to analyze TCDD-treated T cells (Fig. 3c) . To investigate whether the induction of GZMB by TCDD was mediated by AhR, we knocked down AHR expression with siRNA ( Fig. 3d) . Knockdown of AHR significantly decreased the induction of GZMB expression by TCDD (Fig. 3d) . Thus, AhR activation directly or indirectly upregulates the expression of GZMB.
To assess the relevance of granzyme B for the suppressive activity of TCDD-treated T cells, we used the granzyme B inhibitor AAD-CMK (benzyloxycarbonyl-Ala-Ala-Asp-chloromethylketone). AAD-CMK abrogated the suppressive activity of TCDD-treated T cells (Fig. 3e) . However, consistent with published reports 30 , inhibition of caspase-3 activity had no significant effect on the suppressive activity (Fig. 3e) . Moreover, knockdown of GZMB expression with specific siRNA abrogated the suppressive activity of TCDD-treated T cells in vitro (Fig. 3f) . Neutralizing antibodies to other known suppressive molecules, such as IL-10, TGF-β, Fas or FasL, had no significant effect on the suppressive activity of TCDD-treated T cells (data not shown). Together these data show that activation of AhR induces Tr1-like cells that control responder T cells in a granzyme B-dependent manner.
AhR activation plus TGF-b1 induce FOXP3 + T cells TGF-β1 has an important role in the differentiation, maintenance and function of T reg cells 31 . TGF-β1 promotes the differentiation of functional Foxp3 + T reg cells in the mouse 4 ; however, although naive human T cells activated in the presence of TGF-β1 express Foxp3, they are not endowed with suppressive activity 8 . Given the reported effects of AhR [14] [15] [16] 18, 21 and TGF-β1 (ref. 4 ) on mouse Foxp3 + T reg cells, we investigated the combined effect of TGF-β1 and TCDDmediated activation of AhR on naive human T cells.
Naive T cells activated in the presence of TGF-β1 and TCDD showed a significantly smaller proliferative response after being restimulated with beads coated with anti-CD3 and anti-CD28 than did control or TGF-β1-treated T cells (Fig. 4a) . Furthermore, activation of T cells in the presence of TGF-β1 or of TGF-β1 plus TCDD resulted in significant upregulation of AHR expression (Fig. 4b,  left) . The upregulation of AHR expression by TGF-β1 led to only a little induction of the AhR-controlled gene CYP1A1, but we achieved higher CYP1A1 expression after treating cells with both TGF-β1 and TCDD (Fig. 4b, right) .
We then analyzed the expression of lineage-specific transcription factors in T cells treated with TCDD and TGF-β1. The upregulation of FOXP3 was similar in naive human T cells treated with TGF-β1 and in those treated with TGF-β1 plus TCDD (Fig. 4c) . This upregulation of FOXP3 expression was 50 times greater than the upregulation that followed treatment with TCDD alone (Figs. 1c and 4c) and we also detected it by flow cytometry (Supplementary Figs. 2  and 5) . Treatment with TGF-β1 plus TCDD, but not with TGF-β1 alone, resulted in significant downregulation of the expression of GATA3 and TBX21 (Fig. 4c) . Moreover, treatment with TGF-β1 plus TCDD suppressed the induction of RORC expression triggered by TGF-β1 alone (Fig. 4c) . In T cells treated with TGF-β1 plus TCDD, the expression of TGFB1 was upregulated (Fig. 4d) and the expression of IFNA1, IL2 and IL17 was downregulated, but that of IL10 and TNF did not change (Fig. 4d) .
TCDD plus TGF-b1 induce functional Foxp3 + T reg cells Naive human T cells activated in the presence of TGF-β1 express Foxp3 but do not have suppressive activity 8 . However, T cells treated with TGF-β1 plus TCDD were suppressive in vitro (Fig. 5a) , and their suppressive activity was greater than that of T cells treated with TCDD alone (Figs. 2a and 5a) . The suppressive activity of T cells treated with TGF-β1 and TCDD was mediated by a cell contact-dependent mechanism (Fig. 5b) independently of granzyme B (Supplementary Fig. 6 ).
We used gene microarray to analyze the transcriptional profile of T cells treated with TGFβ-1 and TCDD to identify the mechanism of suppression used by human T reg cells induced by AhR stimulation in presence of TGF-β1. We found significantly higher expression of ENTPD1 (encoding CD39) in T cells treated with TGF-β plus TCDD (Fig. 5c) . We obtained similar results when we analyzed ENTPD1 expression in an independent set of samples by quantitative real-time PCR (Fig. 5d) and by flow cytometry (Fig. 5e) . To investigate whether the induction of ENTPD1 was mediated by AhR, we knocked down AHR expression with short hairpin RNA (shRNA). After 6 d, AHR expression was 45% lower (Fig. 5f) . The knockdown of AHR resulted in significantly lower ENTPD1 expression in T cells differentiated with TGF-β1 plus TCDD (Fig. 5f) . Thus, AhR activation in the presence of TGF-β1 controls the expression of ENTPD1.
CD39 (ENTPD1) hydrolyzes ATP and mediates the suppressive activity of murine and human Foxp3 + T reg cells 32 . Neutralizing antibodies to CD39 abrogated the suppressive activity of T cells treated with TGF-β plus TCDD (Fig. 5g) . Together these results show that 
A r t i c l e s activation of AhR in the presence of TGF-β induces functional human Foxp3 + T reg cells that suppress effector T cells by a CD39-dependent mechanism.
AhR activation plus TGF-b1 induces Smad1 and Aiolos Naive human T cells activated in the presence of TGF-β1 express Foxp3 but do not have suppressive activity 8 . On the basis of the finding that suppressive human Foxp3 + T reg cells can be induced by TGF-β1 plus TCDD, we hypothesized that AhR activation might induce additional transcription factors needed for the induction of functional Foxp3 + T reg cells. Gene microarray showed that expression of the transcription factors Smad1 and Aiolos (encoded by IKZF3) was significantly upregulated in T cells treated with TGF-β1 plus TCDD (Fig. 6a,b) . We confirmed that upregulation by quantitative real-time PCR in an independent set of samples (Fig. 6c,d ). To investigate whether the induction of Smad1 and Aiolos was mediated by AhR, we knocked down AHR expression with shRNA. Knockdown of AHR resulted in significantly lower expression of SMAD1 and IKZF3 in T cells differentiated with TGF-β1 plus TCDD (Fig. 6e,f) . Thus, AhR activation in the presence of TGF-β1 upregulates the expression of Smad1 and Aiolos.
Smad1 regulates Foxp3 enhancer activity
Smad1 belongs to a family of transcription factors involved in TGF-β signaling. Smad3 binds to an enhancer in the region of positions +2079 to +2198 of human FOXP3 and thus controls its expression 33 . Because Smad3 and Smad1 recognize similar DNA-binding motifs 34 , we investigated the binding of Smad1 to the enhancer in this region (+2079 to +2198) in FOXP3 in human T cells treated with TGF-β1 and TCDD. Using ChIP, we found that the interaction between Smad1 and the FOXP3 enhancer located in this region was upregulated in T cells treated with TGF-β1 and TCDD compared with that of control T cells (Fig. 7a) .
To investigate the functional relevance of the binding of Smad1 to the enhancer we transfected the EL4 mouse lymphoma cell line with a reporter system in which six copies of the Smad-binding motif in the Foxp3 enhancer in the region of positions +2079 to +2198 control the expression of firefly luciferase 33 (Supplementary Fig. 7a ). As reported before 33 luciferase activity was induced after cotransfection with a vector encoding Smad3 (Fig. 7b) . Moreover, luciferase activity was also induced after cotransfection with a construct encoding Smad1 (Fig. 7b) . We obtained similar results when we investigated the ability of constructs encoding Smad1 or Smad3 to activate a luciferase reporter controlled by the Foxp3 enhancer in this region 33 (Fig. 7c and Supplementary  Fig. 7b) . Thus, stimulation with TGF-β1 concurrent with activation of AhR results in the induction of Smad1, which binds and activates the Foxp3 enhancer in the region of positions +2079 to +2198.
To investigate the effect of the binding and activation of the FOXP3 enhancer in that region by Smad1 on FOXP3 expression, we knocked down SMAD1 expression with lentivirus-delivered shRNA in naive human T cells activated in the presence of anti-CD3, anti-CD28 and IL-2 with TGF-β1 and TCDD. The expression of SMAD1 mRNA was 80% lower after treatment with the Smad1-specific shRNA (Fig. 7d) . Correspondingly, the knockdown of SMAD1 led to significantly lower expression of FOXP3 and ENTPD1 by Foxp3 + T reg cells induced with TGF-β1 and TCDD. Conversely, IL2 expression was significantly upregulated after knockdown of SMAD1 (Fig. 7d) . Moreover, the knockdown of SMAD1 led to significantly lower suppressive activity of Foxp3 + T reg cells induced with TGF-β1 plus TCDD (Fig. 7e) . Together these data show that Smad1 controls the expression of FOXP3 and the suppressive activity in Foxp3 + T reg cells that have been differentiated with TCDD and TGF-β1.
Aiolos-Foxp3 interaction silences IL2 expression
Aiolos is a transcription factor of the Ikaros family; members of this family are important in the development of hematopoietic cells 35 . Eos, another member of the Ikaros family, forms a complex with Foxp3 and mediates the silencing of target genes such as Il2 in mouse Foxp3 + T reg cells 36 . DNA target sequences bound by members of the Ikaros family are highly conserved 37 , and Eos interacts with the Il2 promoter 36 , so we used ChIP assays to investigate whether Aiolos binds the IL2 promoter in human T cells activated with TGF-β1 and TCDD. The binding of Aiolos to the Eos-binding site in the IL2 promoter was greater in naive T cells activated in the presence of TGF-β1 and TCDD (Fig. 8a) .
Eos and Foxp3 form a protein complex that represses the expression of target genes 36 . To investigate whether Aiolos and Foxp3 can interact physically, we did coimmunoprecipitation studies with constructs encoding Foxp3 and Flag-tagged Aiolos. Anti-Foxp3 and anti-Aiolos precipitated a protein complex containing Foxp3 and Aiolos, but control IgG did not (Fig. 8b) . Thus, Foxp3 and Aiolos physically associate with each other.
Aiolos can form homodimers and can also form complexes with other proteins through interactions mediated by zinc fingers in its A r t i c l e s C-terminal domain 37 . There are also four more zinc fingers in the N-terminal portion of the protein. To determine whether the interaction of Aiolos with Foxp3 was mediated by its C-terminal domain, we did coimmunoprecipitation studies with a vector encoding the Aio-1-5a isoform of Aiolos, which lacks the two C-terminal zinc fingers involved in homo-and heterodimerization 38 (Fig. 8c) . As a control, we used the Aio-Δ3,4,5 isoform, which lacks all the zinc fingers at the N terminus but retains the C-terminal dimerization domain (Fig. 8c) . Like full-length Aiolos, Aio-Δ3,4,5 interacted with Foxp3 (Fig. 8d) . However, the deletion of the C-terminal domain in Aio-1-5a disrupted its interaction with Foxp3 (Fig. 8d) . Therefore, like Eos, Aiolos forms a complex with Foxp3 through interactions mediated by its C-terminal zinc fingers. Eos participates in the repression of Il2 expression by Foxp3 (ref. 36) . Naive T cells activated in the presence of TGF-β1 plus TCDD had lower IL2 expression (Fig. 4d) and concomitant induction of Aiolos (Fig. 6b,d) . To investigate the role of Aiolos in the repression of IL2 expression by Foxp3, we did knockdown experiments with naive human T cells activated in the presence of anti-CD3, anti-CD28 and IL-2 with TGF-β1 and TCDD using lentivirus-delivered shRNA specific for IKZF3. Treatment with shRNA resulted in significantly lower expression of IKZF3 (Fig. 8e) and higher IL2 expression in T cells treated with TGF-β1 plus TCDD (Fig. 8e) . Foxp3 expression is independent of Eos 36 . Accordingly, the knockdown of IKZF3 did not result in significant changes in FOXP3 expression (Fig. 8e) . However, the knockdown of IKZF3 led to significantly lower suppressive activity of Foxp3 + T reg cells induced with TGF-β1 plus TCDD (Fig. 8f) . Together these data suggest that Foxp3 forms a complex with Aiolos to repress target genes and control the suppressive activity of Foxp3 + T reg cells that have been differentiated with TCDD and TGF-β1. 10,11) . The phenotypic diversity of Tr1 cells and the disparate settings that promote their differentiation 10, 11 suggest that there are several lineages of CD4 + IL-10 + T reg cells. Accordingly, transcription factors such as Sp1, Sp3, C/EBP-β, IRF1, STAT3 and c-MAF can activate the Il10 promoter 24 . In particular, c-MAF has been proposed to be a universal transcription factor that regulates the production of IL-10 by T cells 24 The production of IL-10 does not necessarily result in a suppressive phenotype; proinflammatory IL-9-producing helper T cells, for example, have high expression of IL-10 (ref. 40) . We found that the Tr1-like cells induced by AhR activation suppressed effector T cells by a granzyme B-dependent mechanism independently of IL-10. TCDD-induced mouse Tr1-like cells also express granzyme B 41 . However, we do not believe that AhR alone or in combination with c-Maf acts as a lineage-specification transcription factor for Tr1 cells. AhR is expressed by many lineages in addition to Tr1 cells, such as Foxp3 + T reg cells 14, 16 and T H 17 cells 14, 16, 20 . Similarly, c-Maf is expressed not only by Tr1 cells but also by T H 1 cells 24 and T H 17 cells 25 . Instead, our findings, along with those of Apoteh et al. 39 , suggest that AhR acts in synergy with c-Maf and other transcription factors to control part of the transcriptional program linked to Tr1 cell differentiation.
In humans, neither forced Foxp3 overexpression 7 nor Foxp3 expression triggered by TGF-β1 alone 8 results in the differentiation of suppressive Foxp3 + T reg cells, which indicates that additional signals beyond those controlled by Foxp3 are required for the generation of functional Foxp3 + T reg cells. We found that the differentiation of suppressive Foxp3 + T reg cells by the concurrent activation of AhR and TGF-β1 signaling required the combined activities of Smad1 and Aiolos. A conserved noncoding sequence (CNS-1) in Foxp3 controls the differentiation of Foxp3 + iT reg cells in gut-associated lymphoid tissue 42 . The CNS-1 region in FOXP3 contains a functional Smadbinding site that interacts with Smad3 and drives FOXP3 expression upon activation with TGF-β1 (ref. 33 ). We found that T cell activation in the presence of TGF-β1 plus TCDD induced the expression of Smad1, which interacted with the Smad-binding motif in CNS-1 to promote FOXP3 expression. It has been proposed that stable Foxp3 expression is achieved when the transcription factors NFAT, Smad, CREB and c-Rel form an enhanceosome that transactivates FOXP3 (ref. 43 ). In this model, various members of the Smad or NFAT family can be incorporated into the enhanceosome that drives FOXP3 expression 43 . Our data suggest that in the Foxp3 + iT reg cells induced in vitro by the concomitant activation of TGF-β1 and AhR signaling, Smad1 alone or in combination with Smad3 and/or Smad4 interacts with CNS-1 to activate FOXP3 expression.
Proteins of the Ikaros family share a DNA-binding domain that recognizes sequences containing the GGGA core motif 37 . Accordingly, we found that Aiolos and Eos bound the same DNA motif in IL2 to inhibit its expression. Members of the Ikaros family control gene expression by anchoring protein complexes that regulate chromatin remodeling and histone deacetylation in target genes 44 . In addition, proteins in the Ikaros family can also repress gene expression by mechanisms independent of chromatin remodeling and histone deacetylation 45 . Together our data suggest that Aiolos interacts with Foxp3 to silence the transcriptional program of effector T cells and further promote the differentiation of functional Foxp3 + T reg cells.
It has been suggested that Tr1 cells and Foxp3 + iT reg cells constitute alternative fates of T cell differentiation whose immunoregulatory function might be partially redundant in gut-associated lymphoid tissue 42 . Here we have reported that depending on the cytokine milieu, AhR activation promoted the differentiation of human Tr1 or Foxp3 + T reg cells. Thus, it is conceivable that AhR ligands provided by the diet 46 or the intestinal flora 47 influence the differentiation of Tr1, Foxp3 + iT reg and T H 17 cells in vivo. Moreover, our data suggest that AhR ligands can be used to promote iT reg cell differentiation in vitro, which could be exploited to generate functional iT reg cells in vitro for adoptive-transfer regimes aimed at reestablishing immune tolerance. Alternatively, nontoxic AhR ligands could constitute potential new drugs for the therapeutic induction of T reg cells in vivo and the management of autoimmune disorders.
